SK Biopharm Sues Two Drugmakers to Block Xcopri Copies (Correct)

SK Biopharmaceuticals Co. filed a federal lawsuit alleging that copies of Xcopri proposed by Aurobindo Pharmaceuticals Ltd. and Zenara Pharma Pvt. Ltd. infringe patents for the epilepsy drug, whose sales provide nearly all of SK’s revenue.

SK Biopharm and its SK Life Science Inc. unit, both subsidiaries of South Korea-based SK Inc., allege that Aurobindo’s generic versions of Xcopri infringe US Patent No. 11,654,133, and Zenara’s copies infringe that and US Patent No. 7,598,279, according to a complaint filed June 18 in the US District Court for the District of Delaware. Neither Aurobindo nor Zenara immediately responded to ...